en English
en Englishfr Frenchde Germanit Italianpt Portuguesees Spanish
en English
en Englishfr Frenchde Germanit Italianpt Portuguesees Spanish

Clinical Trial Finder

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Study Purpose

The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

 No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

 Interventional
Eligible Ages 40 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Male or female patients aged ≥40 years based on the date of the written informed consent form. 2. Diagnosis of IPF as defined by American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines. 3. In a stable condition and suitable for study participation based on the results of medical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluation. 4. Subjects with background pirfenidone or nintedanib may be enrolled if their regimen of antifibrotic therapy has been stable for ≥ 8 weeks prior to Visit 1. Meeting all of the following criteria during the screening period: 1. FVC ≥40% predicted of normal. 2. DLCO corrected for Hgb ≥25% and <80% predicted of normal. 3. forced expiratory volume in the first second/FVC (FEV1/FVC) ratio >0.7 based on pre-bronchodilator value.

Exclusion Criteria:

1. Acute IPF exacerbation within 4 months prior to Visit 1 and/or Day 1, as determined by the investigator. 2. Patients who are unwilling to refrain from smoking within 3 months prior to screening and until the end of the study. 3. Female patients who are pregnant or nursing. 4. Abnormal ECG findings

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

 NCT05975983
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

 Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

 InSilico Medicine Hong Kong Limited
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

 N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

 Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

 Idiopathic Pulmonary Fibrosis (IPF)
Arms & Interventions

Arms

Experimental: INS018_055

Group 1: INS018_055 once daily up to 12 weeks, low dose Group 2: INS018_055 twice daily up to 12 weeks, low dose Group 3: INS018_055 once daily up to 12 weeks, high dose

Placebo Comparator: Placebo

Group 4: Placebo once or twice daily up to 12 weeks

Interventions

Drug: - INS018_055

Pharmaceutical formulation: Capsules Mode of Administration: Oral

Drug: - Placebo

Pharmaceutical formulation: Capsules Mode of Administration: Oral

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Keck School of Medicine of USC, Los Angeles, California

Status

Not yet recruiting

Address

Keck School of Medicine of USC

Los Angeles, California, 90033

Florida Lung Asthma and Sleep Specialist, Celebration, Florida

Status

Recruiting

Address

Florida Lung Asthma and Sleep Specialist

Celebration, Florida, 34747-1818

Southeastern Research Center, Winston-Salem, North Carolina

Status

Recruiting

Address

Southeastern Research Center

Winston-Salem, North Carolina, 27103-4007

Oklahoma City, Oklahoma

Status

Not yet recruiting

Address

University of Oklahoma Health Sciences Center (OUHSC)

Oklahoma City, Oklahoma, 73104-5417

Bogan Sleep Consultants, LLC, Columbia, South Carolina

Status

Recruiting

Address

Bogan Sleep Consultants, LLC

Columbia, South Carolina, 29201-2953

Dallas, Texas

Status

Not yet recruiting

Address

Univerity of Texas Southwestern Medical Center

Dallas, Texas, 75235-6243

Metroplex Pulmonary and Sleep Center, McKinney, Texas

Status

Recruiting

Address

Metroplex Pulmonary and Sleep Center

McKinney, Texas, 75069-1898

Research Centers of America, McKinney, Texas

Status

Not yet recruiting

Address

Research Centers of America

McKinney, Texas, 75071

Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.